Harvard Bioscience reported second quarter 2026 revenue of $22.7 million, an 11% increase year-over-year from $20.5 million, and raised its full-year 2026 revenue growth guidance to 3%-5%. The company posted a net loss of ($2.9) million for the quarter compared to ($2.3) million in the prior year period, while adjusted EBITDA improved to $1.7 million from $1.5 million. Full-year adjusted gross margin is now targeted between 57% and 59%, with adjusted EBITDA growth expected between 6% and 10%. The filing notes a 1-for-10 reverse stock split effective March 13, 2026. Harvard Bioscience develops, manufactures, and sells technologies for life science applications including research, drug discovery, and preclinical testing.

Harvard Bioscience filed an 8-K to disclose a corporate slide presentation under Regulation FD. The filing provides updated financial guidance for the third quarter and full year of fiscal 2026, raising FY26 revenue growth expectations to 3-5% from 2-4%. The company projects Q3 2026 revenue between $21.0 million and $22.6 million with adjusted EBITDA between $1.5 million and $2.5 million. Operational updates include a strategic manufacturing consolidation, Project Viking, which aims to close the Holliston, MA plant by Q1 2027 to generate approximately $3 million in adjusted EBITDA savings in 2027 and $4 million annually thereafter. The presentation also details a recent debt refinancing structure involving BroadOak and highlights new executive leadership appointments. Harvard Bioscience operates in the life sciences tools industry, providing translational research equipment for drug discovery and preclinical development.